BidaskClub upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a buy rating in a report released on Thursday morning.
Several other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of OraSure Technologies from a sell rating to a hold rating in a report on Saturday, December 2nd. ValuEngine lowered shares of OraSure Technologies from a buy rating to a hold rating in a research report on Thursday, November 2nd. Jefferies Group lowered shares of OraSure Technologies from a buy rating to a hold rating in a research report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a buy rating and issued a $22.00 price objective on shares of OraSure Technologies in a research report on Tuesday, September 19th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $19.65.
OraSure Technologies (OSUR) opened at $18.90 on Thursday. The stock has a market cap of $1,150.00, a P/E ratio of 36.35, a P/E/G ratio of 3.61 and a beta of 1.28. OraSure Technologies has a 1-year low of $8.39 and a 1-year high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.09. The firm had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.11 earnings per share. equities research analysts forecast that OraSure Technologies will post 0.42 earnings per share for the current fiscal year.
In other OraSure Technologies news, CEO Douglas A. Michels sold 22,923 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mara G. Aspinall purchased 5,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The shares were purchased at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $71,150. The disclosure for this purchase can be found here. Insiders own 6.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Belpointe Asset Management LLC bought a new stake in OraSure Technologies during the third quarter worth $315,000. Oppenheimer Asset Management Inc. acquired a new position in shares of OraSure Technologies in the third quarter valued at $186,000. Pier Capital LLC acquired a new position in shares of OraSure Technologies in the third quarter valued at $5,819,000. OxFORD Asset Management LLP acquired a new position in shares of OraSure Technologies in the third quarter valued at $1,323,000. Finally, KBC Group NV increased its holdings in shares of OraSure Technologies by 80.5% in the third quarter. KBC Group NV now owns 88,502 shares of the medical instruments supplier’s stock valued at $1,991,000 after purchasing an additional 39,469 shares during the last quarter. 94.43% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://transcriptdaily.com/2017/12/25/orasure-technologies-osur-upgraded-by-bidaskclub-to-buy.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.